Convergence Deficits in Myoclonus‐Dystonia Point to Cerebellar Impairment
Movement Disorders Clinical Practice · 2026-06 · 13 (6) · 1488-1495
DOI: 10.1002/mdc3.70521 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 12.01.2026. Verfasst von Skadi Gerkensmeier und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Hospital Schleswig-Holstein, Lübeck, Germany. Hauptthemen laut MEDLINE: Cerebellar Diseases, Dystonic Disorders, Ocular Motility Disorders, Convergence, Ocular. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Dystonia Medical Research Foundation.
Abstract (Originalsprache)
Background
Myoclonus‐dystonia (M‐D) is a monogenic movement disorder, with proposed cerebellar dysfunction. Vergence eye movement deficits, characteristics of degenerative cerebellar disease, have not been studied in M‐D. Cerebellar transcranial alternating current stimulation (tACS) is considered a potential therapeutic approach.
Objectives
To assess vergence and prosaccade performance as markers of cerebellar dysfunction in M‐D and to evaluate the effects of cerebellar 50 Hz tACS on these eye movements.
Methods
Vergence and prosaccade performance were examined in 14 M‐D patients carrying pathogenic SGCE variants and 14 healthy controls. A subgroup ( n = 7) received real and sham 50 Hz cerebellar tACS in a randomized, double‐blind design.
Results
M‐D patients showed prolonged latency and reduced gain of convergence compared to controls. Divergence did not differ between groups. Prosaccade peak velocity was reduced in M‐D patients. 50 Hz cerebellar tACS showed no effect on eye movements.
Conclusion
Impaired convergence supports cerebellar involvement in M‐D. Further studies should identify affected pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University Hospital Schleswig-Holstein, Lübeck, Germany.
- Institute of Systems Motor Science, University of Lübeck, Lübeck, Germany.
- Department of Psychiatry and Psychotherapy, University of Lübeck, Lübeck, Germany.
- Center of Brain, Behavior and Metabolism (CBBM), University of Lübeck, Lübeck, Germany.
- Institute of Psychology II, University of Lübeck, Lübeck, Germany.
- Krembil Research Institute, University Health Network, Toronto, Ontario, Canada.
ORCID-Profile: Skadi Gerkensmeier, Christina Bolte, Jan-Ole Radecke, Feline Hamami, Andreas Sprenger, Christoph Helmchen, Robert Chen, Marcus Callister, Talyta Cortez Grippe, Christine Klein, Norbert Brüggemann, Tobias Bäumer, Alexander Münchau, Anne Weissbach
Förderung
- Deutsche Forschungsgemeinschaft
- Dystonia Medical Research Foundation
Zitieren
APA
Gerkensmeier, S., Bolte, C., Radecke, J. O., Hamami, F., Sprenger, A., Helmchen, C., Chen, R., Callister, M., Cortez Grippe, T., Klein, C., Brüggemann, N., Bäumer, T., Münchau, A., & Weissbach, A. (2026). Convergence Deficits in Myoclonus‐Dystonia Point to Cerebellar Impairment. Movement Disorders Clinical Practice, 13(6), 1488-1495. https://doi.org/10.1002/mdc3.70521
Vancouver
Gerkensmeier S, Bolte C, Radecke JO, Hamami F, Sprenger A, Helmchen C, et al. Convergence Deficits in Myoclonus‐Dystonia Point to Cerebellar Impairment. Movement Disorders Clinical Practice. 2026;13(6):1488-1495. doi:10.1002/mdc3.70521
BibTeX
@article{Gerkensmeier2026,
author = {Gerkensmeier, Skadi and Bolte, Christina and Radecke, Jan-Ole and Hamami, Feline and Sprenger, Andreas and Helmchen, Christoph and Chen, Robert and Callister, Marcus and Cortez Grippe, Talyta and Klein, Christine and Brüggemann, Norbert and Bäumer, Tobias and Münchau, Alexander and Weissbach, Anne},
title = {Convergence Deficits in Myoclonus‐Dystonia Point to Cerebellar Impairment},
journal = {Movement Disorders Clinical Practice},
year = {2026},
volume = {13},
number = {6},
pages = {1488--1495},
doi = {10.1002/mdc3.70521}
}
EUVIMED